KCT0001469招募中未知
Randomized, Double-blind, Placebo-controlled, Dose-escalation, Repeated and Single Oral Dosing Phase I Study to Assess the Safety of Temanogrel When Co-administered with Aspirin and Clopidogrel
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 45(Year)（—）
- 性别
- All
入选标准
- •1)a healthy adult between 20 and 45 years old at the time of visit for screening
- •2)a person who is able to give written consent
- •3)a person between 50 and 85 kg at the time of visit for screening
- •4)a woman who is negative on a serum hCG test at the time of visit and -1D, and is not lactating, and agreed not to lactate until 30 days after the last administration of the drug under clinical trial.
- •5)a woman who agrees on double contraception, medically approved, from the time of visit for screening to 90 days after the last administration of a clinical trial drug, or who had a contraceptive operation no later than 120 days before visit for screening, or who is menopausal
- •6)a man who had a contraceptive operation no later than 120 days before visit for screening, or who agrees on double contraception, medically approved, from the time of visit for screening to 90 days after the last administration of a clinical trial drug, and also agree not to donate sperm
- •7)a person with more than hemoglobin 12 g/dL at the time of screening (a woman with more than hemoglobin 11 g/dL)
- •8)a person whose vital signs were in the normal range at the time of visit for screening, or who is medically determined not to be clinically significant by an investigator
- •9)a person who voluntarily decides to participate in this clinical trial and gives written consent on strict clinical trial compliance
- •10)a person whose blood can be collected during a study period with visit for monitoring
排除标准
- •1)a person with the medical history of gastric ulcer, duodenal ulcer or esophageal ulcer within 90 days from the time of visit for screening
- •2)a person with the medical history of gastrointestinal diseases(e.g. Crohn’s disease, ulcerative colitis, etc.) or surgery(excluding uncomplicated appendectomy or herniotomy) affecting the absorption of a clinical trial drug
- •3)a person with the medical history of blood coagulation disorder or hemorrhagic diseases, or with clinically significant abnormal findings decided by a investigator on blood coagulation test at the time of screening
- •4)a woman with the medical history of dysfunctional uterine bleeding within a year from the time of visit for screening
- •5)a person with the medical history of epilepsy or convulsion
- •6)a person with the medical history of internal organ transplant
- •7)a person expected to be hard to complete a clinical trial because of surgery or medical procedures planned within a clinical trial period
- •8)a person with the medical history of clinically significant new diseases within 30 days from the time of visit for screening according to investigator’s decision
- •9)a person with hypersensitivity reaction to a drug or gelatin, or the medical history of clinically significant hypersensitivity reaction
- •10)a person with the history of drug abuse, or with a positive reaction to a drug possible to be abused on urine drug screening
- •11)a person with the medical history of alcohol abuse within two years from the time of visit for screening
- •12)a person who is a smoker, or with a positive reaction on a urine nicotine test conducted at the time of visit for screening
- •13)a person who donated whole blood within 60 days or constituents of blood within 30 days, or received a blood transfusion within 30 days from the time of visit for screening
- •14)a person taking other clinical trial drugs within 90 days from the time of visit for screening
- •15)a person taking a prescription drug within 30 days, or a contraindicated drug or oriental medicine within 14 days from the time of visit for screening
- •16)a person with a positive reaction to a serum test(hepatitis B test, hepatitis C test, HIV test, syphilis test)
- •17)a person with hepatic enzymes(AST, ALT) more than 2.5 times of the reference upper limit(UNL) or total bilirubin more than 1.5 times of the reference upper limit(UNL) or creatinine more than 1.25 times of the reference upper limit(UNL)
- •18)a person expected to be hard to complete a clinical trial due to physical or mental status according to investigator’s medical decision at the time of visit for screening
- •19)a person decided to be inappropriate to participate in this clinical trial according to investigator’s medical decision on the result of laboratory tests, such as complete blood cell count, general chemical test, clinicochemical urinalysis, and physical examination, vital signs, ECG, other tests excluding exclusion criteria 17 items conducted before subject selection for a clinical trial
研究者
相似试验
进行中（未招募）
1 期
A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients with Type 2 Diabetes Mellitus (T2DM)EUCTR2015-005789-42-Outside-EU/EEASANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT28
招募中
不适用
Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Temanogrel Co-administered with Aspirin and ClopidogrelKCT0001529Ildong pharmaceutical144
进行中（未招募）
1 期
A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients with Type 2 Diabetes Mellitus (T2DM)Pediatric Patients with Type 2 Diabetes Mellitus Not Adequately Controlled with Metformin and/or Basal InsulinMedDRA version: 19.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2015-005789-42-ESSANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT23
进行中（未招募）
1 期
Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF)EUCTR2018-004447-23-CZRespivant Sciences GmbH180
进行中（未招募）
1 期
Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF)Persistent cough in Idiopathic Pulmonary Fibrosis (IPF)MedDRA version: 21.1Level: LLTClassification code 10070801Term: Persistent coughSystem Organ Class: 100000004855EUCTR2018-004447-23-NLRespivant Sciences GmbH180